Adaptive Biotechnologies Highlights New Data at ASCO 2023
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of choice for biopharma companies as evidenced in over a dozen investigational studies across multiple therapeutic approaches SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies … [Read more…]